MINNEAPOLIS, May 7, 2024
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today
announced it will showcase its portfolio of cell and gene therapy
workflow solutions at the upcoming annual meeting of the American
Society of Gene & Cell Therapy (ASGCT), taking place
May 7-11, 2024, in Baltimore, Maryland.
Bio-Techne's booth (#1627) will feature our market-leading
portfolio of high-quality life science research use only (RUO) and
Good Manufacturing Practice (GMP) reagents, immunoassays, automated
proteomic analytical instruments, and multi-omics solutions for
accelerating cell and gene therapy development and manufacturing.
We will also feature our "Immune Cell Therapy Workflow" multimedia
experience, which enables attendees to explore how Bio-Techne's
solutions streamline and accelerate the immune cell processing
workflow.
Bio-Techne will host three speaker sessions during the
conference, featuring both internal experts and customer case
studies. The topics covered will include characterizing
biodistribution and safety of cell and gene therapies, protein
analytics strategies for gene therapy, and advancements in closed
systems and non-viral cell engineering for immune cell therapy
manufacturing.
Additionally, several Bio-Techne scientists will present posters
highlighting our in-house studies in the areas of immune cell
culture, automated spatial multi-omics, and protein or viral vector
characterization. These include investigations into the efficient
activation and expansion of human T cells for CAR-T therapy,
RNA/protein ISH imaging of gene therapy biodistribution and
persistence, and the multiparameter characterization of
adeno-associated virus capsids.
"We are proud to support the advancement of cell and gene
therapy research, development and manufacturing with our robust
portfolio of innovative tools, reagents and workflow solutions,"
said Kim Kelderman, Bio-Techne's
President and Chief Executive Officer. "Bio-Techne's portfolio
plays a critical role in the development of next-generation cell
and gene therapies. Our broad presence at ASGCT will showcase the
many roles Bio-Techne plays in catalyzing advances in science and
medicine, and ultimately enabling patients to live healthier and
longer lives."
Bio-Techne Presentations:
Novel RNAscope™
Multi-omics Spatial Approach to Characterize Biodistribution and
Safety of Cell and Gene Therapies
- Wednesday, May 8th
from 4:45pm – 5:15pm in Room 337-338
- Presented by Sharel Figueredo,
Ph.D.
Protein Analytics Strategies for Gene Therapy – from Viral
Vector Characterization to Clinical Trials
- Thursday, May 9th from
8:30am – 9:30am in Room 324-326
- Presented by Hiren Patel, Ph.D.
(REGENEXBIO Inc.)
- Moderator Chris Heger,
Ph.D.
Advancements in GMP and Closed System Reagents for Immune
Cell Therapy Manufacturing
- Wednesday, May 8th
from 3:45pm -4:00pm in the Exhibit
Hall
- Presented by Miles Smith,
Ph.D.
Bio-Techne Poster Presentations:
Efficient T-cell
Activation and Expansion for CAR-T Therapy is Dependent on a
Complex Interplay of the Starting Donor Population, Activation
Antibodies and Expansion Platform
- Wednesday, May 8th at
12:00 pm
- Presenter: Hatt Heidtman,
Ph.D.
- Abstract 868
Next Generation Protein Characterization of CD19-CAR
Signaling Cascades
- Thursday, May 9th at 12:00 pm
- Presenter: Charles Haitjema,
Ph.D.
- Abstract 1329
A Versatile Assay for Same-Section Spatial Visualization of
Small RNA, mRNA, Exon Junction, Protein and Protein-Protein
Interactions
- Thursday, May 9th at 12:00 pm
- Presenter: Maithreyan Srinivasan, Ph.D.
- Abstract 1397
RNA/Protein Multiomics Imaging Using RNAscope™ Technologies
to Understand Nonclinical Biodistribution (BD) and Persistence of
Gene Therapy (GT) Products
- Thursday, May 9th at 12:00 pm
- Presenter: Maithreyan Srinivasan, Ph.D.
- Abstract 1398
Characterization of Adeno-Associated Virus Capsids by a Novel
Capillary Isoelectric Focusing Based Fractionation Method and
Charge-Detection Mass Spectrometry
- Friday, May 10th at 12:00 pm
- Presenter: Chris Heger,
Ph.D.
- Abstract 1463
About Bio-Techne
Bio-Techne Corporation
(NASDAQ: TECH) is a global life sciences company
providing innovative tools and bioactive reagents for
the research and clinical diagnostic communities. Bio-Techne
products assist scientific investigations into biological
processes and the nature and progress of specific diseases. They
aid in drug discovery efforts and provide the means for accurate
clinical tests and diagnoses. With thousands of products in its
portfolio, Bio-Techne generated over $1.1 billion in net sales in fiscal 2023 and has
approximately 3,100 employees worldwide. For more information
on Bio-Techne and its brands, please visit
http://www.bio-techne.com or follow the Company on social
media at Facebook, LinkedIn, Twitter or YouTube.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-27th-annual-meeting-of-the-american-society-of-gene--cell-therapy-asgct-302138049.html
SOURCE Bio-Techne Corporation